Sigma Labs, Inc. (OTCMKTS:SGLB) Ends Week on Fast Selling

Sigma Labs, Inc. (OTCMKTS:SGLB) is on an upward trend, but remains ambiguous. Just as the ticker was preparing to vault the 12-cent levels and revisit its August peak, it corrected by more than 17% on not unusual Friday selling. Mid-week, SGLB had positive news of securing a grant for research, but by Friday the news were already absorbed by the market, and profit-takers appeared. Selling exceeded $1.02 million.

Monday started with a tentative upward movement, and some buying, but the end of the day should make it clear if SGLB will still be sold after the weekend.

And the claims of SGLB are becoming a bit old- its relationship with General Electric Co. is a few months old. Now, SGLB could hope to add speed and precision to its 3D printing process, as the technology still suffers from slowness. But while this happens, the ticker may go through another correction. On Monday, SGLB was hovering around the 10-cent levels.

On the positive side, SGLB is looking to be a trendsetter in the industry, and to manage to imbed its technologies in as many sectors as possible. Still, the printers and patents are unique enough, so that there is talk of a buyout by an industry giant. So far, nothing binding has appeared, and the stock’s rise is not affected by those news.

Currently, GE mentioned SGLB as a partner in developing an innovative process for creating new components. The main task is to decrease production time by 25%, as the time saved from designing is eaten up by the process of additive printing.

All of this means longer-term potential for SGLB, as well as a low enough and accessible price even for a shorter-term run.

But not even big contracts can help a stock escape the shakedowns. Soligenix, Inc. (OTCBB:SNGX), a pharmaceutical developer that recently received nearly $34 million in grants, also lost some of its market value, sliding from $2.40 and toward $2.10 in the past three days of selling.

Another stock with a strong climb and a promising business model is Decision Diagnostics Corp. (OTCBB:DECN), producer of generic glucose test strips that awaits a decision on its ability to compete with major players in the blood glucose testing market. DECN shot up from 20 to 80 cents in September, but is now drifting sideways, with minor daily corrections.

If you still want to wait out what SGLB has to offer, it is best to realize that the low price is no guarantee for a breakthrough to higher positions. SGLB has a long way to go before becoming a household name, so do your own due diligence before you decide on a time horizon.